We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Acumen® eX3: Viable Alternative for FMAT Analysis
Product News

Acumen® eX3: Viable Alternative for FMAT Analysis

Acumen® eX3: Viable Alternative for FMAT Analysis
Product News

Acumen® eX3: Viable Alternative for FMAT Analysis


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Acumen® eX3: Viable Alternative for FMAT Analysis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TTP LabTech has announced the results of two collaborative studies using its Acumen eX3 fluorescence microplate cytometer. Collectively, these data demonstrate that the eX3 is a flexible and robust screening instrument capable of supporting a large number of different assay formats that are key to current drug discovery and development.

The first collaboration involved the analysis of a hybridoma screen using both the FMAT 8100 HTS system (Applied Biosystems) and an Acumen eX3 laser scanning cytometer. Resultant trends for quantification of cell- and bead-based bound antibody were comparable between the two instruments.

Data demonstrated that the Acumen is suitable for homogeneous binding assays and is a viable alternative to the discontinued FMAT assay detection instruments.

The Acumen eX3’s utility does not stop there and extends beyond simple binding assays into high content screening. A recent collaboration between TTP LabTech and Nerviano Medical Sciences aimed to increase throughput of a complex 4-colour multiplexed cell cycle assay without a deleterious effect on data quality.

The Acumen achieved a 4.5 fold increase in throughput and the results proved to be in good concordance with those of the Cellomics ArrayScan. Acumen is the ideal choice for primary screening. It can identify hits that may be followed up in more detail using the complimentary ArrayScan technology.

Acumen’s strength comes from the combination of high throughput laser scanning data acquisition, plus its simple cytometric approach to data analysis. Both contribute to the generation of robust results.

In addition, data file sizes are smaller than those generated by high content imaging technologies. These key features give Acumen eX3 the ability to achieve throughputs analyzing over 300,000 wells per day, meaning that it has become an enabling platform for screening departments globally.
Advertisement